Clinical Trials Logo

KRAS G13D clinical trials

View clinical trials related to KRAS G13D.

Filter by:
  • None
  • Page 1

NCT ID: NCT05726864 Recruiting - Colorectal Cancer Clinical Trials

A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors

AMPLIFY-7P
Start date: April 14, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1/2 study to assess the safety and efficacy of ELI-002 7P immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide [Amph-CpG-7909] plus a mixture of lipid-conjugated peptide-based antigens [Amph-Peptides 7P]) as adjuvant treatment in subjects with solid tumors with mutated KRAS/NRAS. This study builds on the experience obtained with related product ELI-002 2P, which was studied in protocol ELI-002-001 under IND 26909.